Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)

Gynecologic Oncology(2020)10.1016/j.ygyno.2019.12.034Source: DataRank Database

Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) is a research paper published in Gynecologic Oncology (2020). On theSindex it has a DataRank of 5.8. It has been cited 155 times, with 100 citing works in its 1-hop citation network.

N/A

5.8DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access155 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02257528

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 9.49)OA: greenTopics (51)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 13%Citation Network 87%

Base Score Contribution

0.757

From this paper's citation signal

Citation Network Contribution

5.1

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
Annals of Translational Medicine202045 citations15 referencesContributes 0.255
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
New England Journal of Medicine20211,004 citations28 referencesContributes 0.247
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study
International Journal of Gynecological Cancer202327 citations15 referencesContributes 0.222
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
The Lancet2023218 citations25 referencesContributes 0.216
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Gynecologic Oncology202075 citations21 referencesContributes 0.206

Authors (12)

Wei Deng ORCID,Michael Frumovitz ORCID,Natália Buza ORCID,Stefania Bellone ORCID,Warner K. Huh ORCID

Live enrichment

PubMed:31924334 PMC:PMC7127981 OpenAlex:https://openalex.org/W3000736809

NCATS NIH HHS

Grant: UL1 TR001863

NCI NIH HHS

Grant: U10 CA180868

NCI NIH HHS

Grant: UG1 CA233330

NCATS NIH HHS

Grant: UL1 TR003167

NCI NIH HHS

Grant: U10 CA180822

NCI NIH HHS

Grant: P30 CA008748

NCI NIH HHS

Grant: UG1 CA233191

NCI NIH HHS

Grant: U01 CA176067

National Institutes of Health

Grant: 2U10CA180822-06

NRG Oncology - Statistical and Data Management Center

National Institutes of Health

Grant: 5U10CA180868-09

NRG Oncology Network Group Operations Center

National Institutes of Health

Grant: 1U01CA176067-01A1

Integrated genomic analysis of racial disparities in endometrial cancer

National Institutes of Health

FWCI

9.49

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7127981

publisherhttps://api.elsevier.com/content/article/PII:S0090825819318645?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0090825819318645?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ygyno.2019.12.034

Fields of Study

Endometrial and Cervical Cancer TreatmentsCancer Immunotherapy and BiomarkersColorectal and Anal Carcinomas03 medical and health sciences0302 clinical medicineAdultAgedAntineoplastic Agents, ImmunologicalB7-H1 AntigenFemaleHumansMiddle AgedNeoplasm Recurrence, LocalNivolumabProgression-Free SurvivalUterine Cervical NeoplasmsYoung Adult

MeSH Terms

Antineoplastic Agents, ImmunologicalNivolumabProgression-Free SurvivalAdultAgedUterine Cervical NeoplasmsFemaleHumansMiddle AgedNeoplasm Recurrence, LocalYoung AdultB7-H1 Antigen

Keywords

MedicineNivolumabCervical cancerOncologyPhase (matter)Internal medicineCancerImmunotherapyCervical neoplasmsPD-1Immune-checkpoint InhibitorsAdultUterine Cervical NeoplasmsMiddle AgedB7-H1 AntigenProgression-Free SurvivalYoung AdultAntineoplastic Agents, ImmunologicalHumansFemaleNeoplasm Recurrence, LocalAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses

10.6084/m9.figshare.14670178.v1figshare

Additional file 1 of Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses

10.6084/m9.figshare.14670178figshare

Additional file 2 of Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses

10.6084/m9.figshare.14670181figshare

Additional file 2 of Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses

10.6084/m9.figshare.14670181.v1figshare